Join the Bladder Cancer group to help and get support from people like you.
Bladder Cancer News
Related terms: Cancer, Bladder
FDA Approves Inlexzo (gemcitabine intravesical system) for the Treatment of Non-Muscle Invasive Bladder Cancer
September 9, 2025. RARITAN, N.J., September 9, 2025 /PRNewswire/ – Johnson & Johnson (NYSE:JNJ) announced today the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical s...
Medical Debt in Collections Persists After Cancer Diagnosis
TUESDAY, Sept. 2, 2025 – Modest amounts of medical debt in collections persist for years after cancer diagnosis, according to a study published online Aug. 28 in JAMA Oncology. Nishant Uppal, M.D.,...
TAR-200 Monotherapy Promising for BCG-Unresponsive Bladder Cancer
THURSDAY, Aug. 21, 2025 – For patients with Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC), an intravesical gemcitabine-releasing system, TAR-200 ...
Device Eliminates Bladder Cancers in 4 of 5 Cases
MONDAY, Aug. 18, 2025 — A new implant eliminated bladder cancer in more than 4 out of 5 high-risk cases, new clinical trial results show. The miniature pretzel-shaped device, dubbed TAR-200, slowly r...
Firefighters at Higher Risk for Many Cancers
WEDNESDAY, July 30, 2025 — Firefighters work hard saving lives, and in process put their own lives at heightened risk from skin, kidney and other types of cancers, a new American Cancer Society (ACS) ...
Deion Sanders Shares Bladder Cancer Journey, Urges Others to Get Checked
WEDNESDAY, July 30, 2025 — University of Colorado football coach Deion Sanders says he is now cancer-free after an unexpected battle with bladder cancer. Now he’s encouraging others to take charge of ...
Autoantibodies Influence Cancer Response To Immunotherapy, Study Says
MONDAY, July 28, 2025 — Cutting-edge immunotherapy drugs are incredibly effective against some cancers but barely put a dent in others – and researchers might now know why. Patients’ own autoa...
FDA Approves Zusduri (mitomycin) for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--Jun. 12, 2025-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and s...
FDA Approves Imfinzi (durvalumab) for Muscle Invasive Bladder Cancer
On March 28, 2025, the Food and Drug Administration approved durvalumab (Imfinzi, AstraZeneca) with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent durvalumab as adjuvant...
Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer
FRIDAY, Jan. 24, 2025 – Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct treatment (TTCT) for patients with muscle-invasive bladder...
New Therapy Helps Patients With Tough-to-Treat Bladder Cancers
FRIDAY, Dec. 6, 2024 – There's new hope for people battling advanced bladder cancer who do not respond to first-line therapy, researchers report. An experimental new drug with the unwieldy name of...
MS Might Raise a Person's Odds for Cancer
THURSDAY, Oct. 10, 2024b – There's a small but significant increased of certain cancers in people battling multiple sclerosis (MS), new research shows. Those malignancies include cancers of the...
Extended Lymphadenectomy Fails to Improve Survival in Bladder Cancer
THURSDAY, Oct. 3, 2024 – For patients with muscle-invasive bladder cancer, extended lymphadenectomy does not improve disease-free or overall survival compared with standard lymphadenectomy,...
Post-Op Keytruda Boosts Bladder Cancer Outcomes
WEDNESDAY, Sept. 18, 2024 – When given after organ-removal surgery, Keytruda brings patients battling advanced bladder cancers more time cancer-free, a new trial finds. Folks with "high-risk"...
FDA Approves Anktiva (nogapendekin alfa inbakicept-pmln) Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
CULVER CITY, Calif., April 22, 2024 -- ImmunityBio, Inc. (NASDAQ: IBRX), an immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has approved Anktiva (N-803, or ...